AMA submission to the Prescribed List — Consultation Paper 10 — General Use items utilisation, expenditure, and integrity

The AMA argues any assessment of the reasons for changes to the use of some Prescribed List General Use Item product groups must be underpinned by hard data, clinical evidence, expert analysis and the over-riding objective of maximising patient access to safe, high-quality care. For this reason, the AMA believes the government should establish an independent, well-resourced Private Health Systems Authority (PHSA) to bring the necessary clinical expertise and stakeholders together to properly investigate this and other issues affecting the sector.